Previous 10 | Next 10 |
Surface Oncology (NASDAQ: SURF ): Q4 GAAP EPS of -$0.57 in-line. Revenue of $0.44M (-95.5% Y/Y) misses by $1.11M . Press Release More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, ,
CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth...
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert...
Pfizer Misses Q4 Target, offers Soft Guidance Pfizer ( PFE ) stock stumbled as the company reported lower than expected numbers for its fourth quarter. It also provided lackluster guidance for the upcoming FY 2020. The company’s revenue fell as it lost exclusivity on its key drugs...
The FDA has signed off on IND applications from Surface Oncology (NASDAQ: SURF ) for Phase 1 studies of candidates SRF617 and SRF388. More news on: Surface Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Surface Oncology (NASDAQ: SURF ) is up 13.8% postmarket after the FDA cleared Investigational New Drug applications for antibody candidates SRF617 and SRF388. More news on: Surface Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: XLRN +79.4% . SURF +17.2% . DESP +8.7% . KBWB +5.8% . BCRX +4.4% . More news on: Acceleron Pharma Inc., Surface Oncology, Inc., Despegar.com, Corp., Stocks on the move, , , News on ETFs Read more ...
Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring Initial clinical updates for SRF617 and SRF388 expected by the end of 2020 Extends current cash runway into 2022 CAMBRIDGE, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Surfac...
Cancer drug company Forty Seven 's (NASDAQ: FTSV) stock price continues to climb higher following the December release of positive data from a Phase 1 clinical trial involving its lead cancer immunotherapy compound, magrolimab. The stock is up more than 200% since early last month. These...
Investment Thesis Last week, in my research note on direct Trillium (TRIL) rival, Forty Seven (FTSV), I argued that Forty Seven was the pick of the immunology companies developing CD47 antibodies to treat various forms of cancer - including hematologic malignancies, diffuse large B-cell ly...
News, Short Squeeze, Breakout and More Instantly...
Surface Oncology Inc. Company Name:
SURF Stock Symbol:
NASDAQ Market:
Surface Oncology Inc. Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Surface Oncology Inc. (SURF) is expected to report $-0.36 for Q3 2023
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) ("Surface"), a clinical-stage immuno-oncology company d...